share_log

RBC Capital Reiterates Outperform on Pacira BioSciences, Maintains $68 Price Target

Benzinga ·  Oct 3, 2023 10:57

RBC Capital analyst Gregory Renza reiterates Pacira BioSciences (NASDAQ:PCRX) with a Outperform and maintains $68 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment